Eli Lilly has reported promising results from its latest Phase III trial of an experimental oral medication designed to combat obesity. The drug, known as orforglipron,...
Eli Lilly’s recent data indicates that its GLP-1 obesity medication is less effective than a similar product from Novo Nordisk. The company reported that patients lost...